RXR Agonists Enhance Lenalidomide Anti-Myeloma Activity and T Cell Functions while Retaining Glucose-Lowering Effect
Jian Wu(Duke Medical Center), Yubin Kang(Duke University)
Cited by 6
Related Papers
Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma
|Blood|2014|96
The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl‐2 inhibitor (ABT‐199) displays synergistic anti‐myeloma effects in myeloma cells without a t(11;14) translocation
|Cancer Medicine|2018|22
Thioredoxin-1 regulates self-renewal and differentiation of murine hematopoietic stem cells through p53 tumor suppressor
|Experimental Hematology and Oncology|2022|17
The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors
|Cancer Medicine|2020|15
PPAR agonists attenuate lenalidomide's anti-myeloma activity in vitro and in vivo
|Cancer Letters|2022|12